NRx Pharmaceuticals

NRx Pharmaceuticals NRXP Stock

$2.15   -15.686269%
Add to favorites
Market Cap
$95.31M
LOW - HIGH [24H]
$2.13 - $2.53
VOLUME [24H]
$1.47M
P/E Ratio
0
Earnings per share
-$0.33
ISIN
US6294442099
Price   Prediction

NRx Pharmaceuticals Price Chart

Sorry, that's all we've gotfor now...

NRx Pharmaceuticals (NRXP) stock price today is 2.15 USD on Tech Market Small (-15.69% on the day). Updated .

NRx Pharmaceuticals NRXP Financial and Trading Overview

NRx Pharmaceuticals stock price 2.15 USD
Previous Close 2.55 USD
Open 2.53 USD
Bid 2.02 USD x 200
Ask 15 USD x 100
Day's Range 2.14 - 2.53 USD
52 Week Range 1.62 - 5.06 USD
Volume 1.47M USD
Avg. Volume 1.06M USD
Market Cap 95.31M USD
Beta (5Y Monthly) N/A
PE Ratio (TTM) N/A
EPS (TTM) -0.33 USD
Forward Dividend & Yield N/A (0%)
Ex-Dividend Date N/A
1y Target Est 39.25 USD

NRXP Valuation Measures

Enterprise Value 76.46M USD
Trailing P/E N/A
Forward P/E -6.1428576
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm) 22.107439
Price/Book (mrq) N/A
Enterprise Value/Revenue 17.736
Enterprise Value/EBITDA -3.219

Trading Information

NRx Pharmaceuticals Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 19.71%
S&P500 52-Week Change 8.67%
52 Week High 5.06 USD
52 Week Low 1.62 USD
50-Day Moving Average 2.75 USD
200-Day Moving Average 2.98 USD

NRXP Share Statistics

Avg. Volume (3 month) 1.06M USD
Avg. Daily Volume (10-Days) 1.05M USD
Shares Outstanding 44.33M
Float 38.31M
Short Ratio 7.2
% Held by Insiders 4.02%
% Held by Institutions 32.02%
Shares Short 10.46M
Short % of Float 24.99%
Short % of Shares Outstanding 23.96%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio N/A
Last Split Factor 1:10

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2025
Most Recent Quarter (mrq) September 30, 2026
Next Fiscal Year End December 31, 2026

Profitability

Profit Margin 0%
Operating Margin (ttm) -556.55%
Gross Margin 39.96%
EBITDA Margin 0%

Management Effectiveness

Return on Assets (ttm) -70.055%
Return on Equity (ttm) N/A

Income Statement

Revenue (ttm) 4.31M USD
Revenue Per Share (ttm) 0.12 USD
Quarterly Revenue Growth (yoy) 378.90%
Gross Profit (ttm) 1.72M USD
EBITDA -23755000 USD
Net Income Avi to Common (ttm) -19765000 USD
Diluted EPS (ttm) -0.33
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 19.82M USD
Total Cash Per Share (mrq) 0.45 USD
Total Debt (mrq) 978K USD
Total Debt/Equity (mrq) N/A
Current Ratio (mrq) 0.759
Book Value Per Share (mrq) -0.046

Cash Flow Statement

Operating Cash Flow (ttm) -23593000 USD
Levered Free Cash Flow (ttm) -14579500 USD

Profile of NRx Pharmaceuticals

Country United States
State DE
City Wilmington
Address 1201 N. Market Street
ZIP 19801
Phone 484 254 6134
Website https://www.nrxpharma.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 29

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Q&A For NRx Pharmaceuticals Stock

What is a current NRXP stock price?

NRx Pharmaceuticals NRXP stock price today per share is 2.15 USD.

How to purchase NRx Pharmaceuticals stock?

You can buy NRXP shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for NRx Pharmaceuticals?

The stock symbol or ticker of NRx Pharmaceuticals is NRXP.

Which industry does the NRx Pharmaceuticals company belong to?

The NRx Pharmaceuticals industry is Biotechnology.

How many shares does NRx Pharmaceuticals have in circulation?

The max supply of NRx Pharmaceuticals shares is 44.33M.

What is NRx Pharmaceuticals Price to Earnings Ratio (PE Ratio)?

NRx Pharmaceuticals PE Ratio is now.

What was NRx Pharmaceuticals earnings per share over the trailing 12 months (TTM)?

NRx Pharmaceuticals EPS is -0.33 USD over the trailing 12 months.

Which sector does the NRx Pharmaceuticals company belong to?

The NRx Pharmaceuticals sector is Healthcare.

NRx Pharmaceuticals NRXP included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
us US Tech Composite IXIC US 22617.73 USD —
-5.28
10.6B USD — 22513.01 USD — 23837.76 USD — — 10.6B USD —
us US Tech Health Care IXHC US 1282.67 USD —
-1.79
— — 1279.99 USD — 1317.94 USD — — — —
us Stlmt ID US Tech Biotechnology NBX US 4000.62 USD —
-1.26
— — 3927.42 USD — 4148.65 USD — — — —
us US Tech Global Market Composite NQGM US 1743.91 USD —
-3.66
— — 1738.23 USD — 1808.43 USD — — — —
us US Tech Biotechnology NBI US 6781.89 USD —
-1.73
— — 6767.31 USD — 6980.47 USD — — — —
$2.08T
Total marketcap
$125.76B
Total volume
BTC 57.95%   •   ETH 9.84%
Dominance
Select currency